The Review Panel (MHRA)

The Review Panel (MHRA) carries out statutory and non-statutory reviews of proposals, decisions and provisional decisions taken by Medicines and Healthcare Products Regulatory Agency.

Role of the group

The terms of reference for the Review Panel (MHRA) are to:

  • review the provisional determinations made by the Medicines and Healthcare Products Regulatory Agency (MHRA) concerning the classification of a product as a medicine
  • perform the role of the ‘reviewers’ in relation to decisions or proposals made by the MHRA related to the grant, renewal, revocation, suspension, refusal or variation of manufacturer’s or wholesale dealing licences, and UK marketing authorisations (the ‘persons appointed’ role)
  • consider representations about decisions made in relation to advertising

The Review Panel became a departmental expert committee on 1 November 2012 as a result of the Arm’s Length Body (ALB) Review in 2010.

The Code of Practice

Code of Practice on conflicts of interest applies to chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees.  See Code of Practice.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

Current vacancies

If you are interested in joining the Review Panel, please apply via ECSRecruitment@mhra.gov.uk.

Annual report

The Review Panel Annual Report 2020

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

The Review Panel Annual Report 2019

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

The Review Panel Annual Report 2015

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

The Review Panel Annual Report 2014

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

The Review Panel Annual Report 2013

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

The Review Panel's guidance note for the hearing

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use.

Members

The members of the panel are:

  • Mr Neil Mercer LL.B. (Hons) B.A. (Hons) Practising Barrister, Thomas Bingham Chambers, London (Chair)
  • Dr Aomesh Bhatt BSc (Hons), MRCGP, DFFP, MBA Senior Clinical Research Fellow in Translational Medicine, University of Oxford; Tutor in Pharmacology, St Hilda’s College, University of Oxford; Honorary Senior Clinical Fellow, Oxford University Hospitals NHS Trust
  • Mrs Leah Heathman BSc (Hons) MTOPRA Managing Director and Senior Regulatory Consultant, Fusion Pharma Limited
  • Mr Stephen Sharp MA MSc Senior Statistician, University of Cambridge MRC Epidemiology Unit
  • Mrs Rachelle Broadley JP MA (Cantab) Solicitor, Macmillan Cancer Support

Reviewers (participation at specific appeals only) appointed under Sch 5 para 2 of the Human Medicines Regulations 2012 (as amended):

  • Dr Alan Fayaz MD(Res) MRCP FRCA FFPMRCA (University College London Hospital NHS Foundation Trust)
  • Dr Roger Knaggs BSc BMedSci PhD EDPM FFRPS FRPharmS FFPMRCA (University of Nottingham and Primary Integrated Community Solutions
  • Dr Matt Mulvey BSc (Hons) PhD (University of Leeds)
  • Dr Paul Farquhar-Smith MA, MB BChir, MA, PhD, FRCA, FFPMRCA (The Royal Marsden NHS Foundation Trust)